Cargando…

Co-registration Analysis of Fluorodopa and Fluorodeoxyglucose Positron Emission Tomography for Differentiating Multiple System Atrophy Parkinsonism Type From Parkinson's Disease

It is difficult to differentiate between Parkinson's disease and multiple system atrophy parkinsonian subtype (MSA-P) because of the overlap of their signs and symptoms. Enormous efforts have been made to develop positron emission tomography (PET) imaging to differentiate these diseases. This s...

Descripción completa

Detalles Bibliográficos
Autores principales: Xian, Wen-biao, Shi, Xin-chong, Luo, Gan-hua, Yi, Chang, Zhang, Xiang-song, Pei, Zhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093399/
https://www.ncbi.nlm.nih.gov/pubmed/33958998
http://dx.doi.org/10.3389/fnagi.2021.648531
_version_ 1783687799993532416
author Xian, Wen-biao
Shi, Xin-chong
Luo, Gan-hua
Yi, Chang
Zhang, Xiang-song
Pei, Zhong
author_facet Xian, Wen-biao
Shi, Xin-chong
Luo, Gan-hua
Yi, Chang
Zhang, Xiang-song
Pei, Zhong
author_sort Xian, Wen-biao
collection PubMed
description It is difficult to differentiate between Parkinson's disease and multiple system atrophy parkinsonian subtype (MSA-P) because of the overlap of their signs and symptoms. Enormous efforts have been made to develop positron emission tomography (PET) imaging to differentiate these diseases. This study aimed to investigate the co-registration analysis of (18)F-fluorodopa and (18)F-flurodeoxyglucose PET images to visualize the difference between Parkinson's disease and MSA-P. We enrolled 29 Parkinson's disease patients, 28 MSA-P patients, and 10 healthy controls, who underwent both (18)F-fluorodopa and (18)F-flurodeoxyglucose PET scans. Patients with Parkinson's disease and MSA-P exhibited reduced bilateral striatal (18)F-fluorodopa uptake (p < 0.05, vs. healthy controls). Both regional specific uptake ratio analysis and statistical parametric mapping analysis of (18)F-flurodeoxyglucose PET revealed hypometabolism in the bilateral putamen of MSA-P patients and hypermetabolism in the bilateral putamen of Parkinson's disease patients. There was a significant positive correlation between (18)F-flurodeoxyglucose uptake and (18)F-fluorodopa uptake in the contralateral posterior putamen of MSA-P patients (rs = 0.558, p = 0.002). Both (18)F-flurodeoxyglucose and (18)F-fluorodopa PET images showed that the striatum was rabbit-shaped in the healthy control group segmentation analysis. A defective rabbit-shaped striatum was observed in the (18)F-fluorodopa PET image of patients with Parkinson's disease and MSA-P. In the segmentation analysis of (18)F-flurodeoxyglucose PET image, an intact rabbit-shaped striatum was observed in Parkinson's disease patients, whereas a defective rabbit-shaped striatum was observed in MSA-P patients. These findings suggest that there were significant differences in the co-registration analysis of (18)F-flurodeoxyglucose and (18)F-fluorodopa PET images, which could be used in the individual analysis to differentiate Parkinson's disease from MSA-P.
format Online
Article
Text
id pubmed-8093399
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80933992021-05-05 Co-registration Analysis of Fluorodopa and Fluorodeoxyglucose Positron Emission Tomography for Differentiating Multiple System Atrophy Parkinsonism Type From Parkinson's Disease Xian, Wen-biao Shi, Xin-chong Luo, Gan-hua Yi, Chang Zhang, Xiang-song Pei, Zhong Front Aging Neurosci Neuroscience It is difficult to differentiate between Parkinson's disease and multiple system atrophy parkinsonian subtype (MSA-P) because of the overlap of their signs and symptoms. Enormous efforts have been made to develop positron emission tomography (PET) imaging to differentiate these diseases. This study aimed to investigate the co-registration analysis of (18)F-fluorodopa and (18)F-flurodeoxyglucose PET images to visualize the difference between Parkinson's disease and MSA-P. We enrolled 29 Parkinson's disease patients, 28 MSA-P patients, and 10 healthy controls, who underwent both (18)F-fluorodopa and (18)F-flurodeoxyglucose PET scans. Patients with Parkinson's disease and MSA-P exhibited reduced bilateral striatal (18)F-fluorodopa uptake (p < 0.05, vs. healthy controls). Both regional specific uptake ratio analysis and statistical parametric mapping analysis of (18)F-flurodeoxyglucose PET revealed hypometabolism in the bilateral putamen of MSA-P patients and hypermetabolism in the bilateral putamen of Parkinson's disease patients. There was a significant positive correlation between (18)F-flurodeoxyglucose uptake and (18)F-fluorodopa uptake in the contralateral posterior putamen of MSA-P patients (rs = 0.558, p = 0.002). Both (18)F-flurodeoxyglucose and (18)F-fluorodopa PET images showed that the striatum was rabbit-shaped in the healthy control group segmentation analysis. A defective rabbit-shaped striatum was observed in the (18)F-fluorodopa PET image of patients with Parkinson's disease and MSA-P. In the segmentation analysis of (18)F-flurodeoxyglucose PET image, an intact rabbit-shaped striatum was observed in Parkinson's disease patients, whereas a defective rabbit-shaped striatum was observed in MSA-P patients. These findings suggest that there were significant differences in the co-registration analysis of (18)F-flurodeoxyglucose and (18)F-fluorodopa PET images, which could be used in the individual analysis to differentiate Parkinson's disease from MSA-P. Frontiers Media S.A. 2021-04-20 /pmc/articles/PMC8093399/ /pubmed/33958998 http://dx.doi.org/10.3389/fnagi.2021.648531 Text en Copyright © 2021 Xian, Shi, Luo, Yi, Zhang and Pei. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Xian, Wen-biao
Shi, Xin-chong
Luo, Gan-hua
Yi, Chang
Zhang, Xiang-song
Pei, Zhong
Co-registration Analysis of Fluorodopa and Fluorodeoxyglucose Positron Emission Tomography for Differentiating Multiple System Atrophy Parkinsonism Type From Parkinson's Disease
title Co-registration Analysis of Fluorodopa and Fluorodeoxyglucose Positron Emission Tomography for Differentiating Multiple System Atrophy Parkinsonism Type From Parkinson's Disease
title_full Co-registration Analysis of Fluorodopa and Fluorodeoxyglucose Positron Emission Tomography for Differentiating Multiple System Atrophy Parkinsonism Type From Parkinson's Disease
title_fullStr Co-registration Analysis of Fluorodopa and Fluorodeoxyglucose Positron Emission Tomography for Differentiating Multiple System Atrophy Parkinsonism Type From Parkinson's Disease
title_full_unstemmed Co-registration Analysis of Fluorodopa and Fluorodeoxyglucose Positron Emission Tomography for Differentiating Multiple System Atrophy Parkinsonism Type From Parkinson's Disease
title_short Co-registration Analysis of Fluorodopa and Fluorodeoxyglucose Positron Emission Tomography for Differentiating Multiple System Atrophy Parkinsonism Type From Parkinson's Disease
title_sort co-registration analysis of fluorodopa and fluorodeoxyglucose positron emission tomography for differentiating multiple system atrophy parkinsonism type from parkinson's disease
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093399/
https://www.ncbi.nlm.nih.gov/pubmed/33958998
http://dx.doi.org/10.3389/fnagi.2021.648531
work_keys_str_mv AT xianwenbiao coregistrationanalysisoffluorodopaandfluorodeoxyglucosepositronemissiontomographyfordifferentiatingmultiplesystematrophyparkinsonismtypefromparkinsonsdisease
AT shixinchong coregistrationanalysisoffluorodopaandfluorodeoxyglucosepositronemissiontomographyfordifferentiatingmultiplesystematrophyparkinsonismtypefromparkinsonsdisease
AT luoganhua coregistrationanalysisoffluorodopaandfluorodeoxyglucosepositronemissiontomographyfordifferentiatingmultiplesystematrophyparkinsonismtypefromparkinsonsdisease
AT yichang coregistrationanalysisoffluorodopaandfluorodeoxyglucosepositronemissiontomographyfordifferentiatingmultiplesystematrophyparkinsonismtypefromparkinsonsdisease
AT zhangxiangsong coregistrationanalysisoffluorodopaandfluorodeoxyglucosepositronemissiontomographyfordifferentiatingmultiplesystematrophyparkinsonismtypefromparkinsonsdisease
AT peizhong coregistrationanalysisoffluorodopaandfluorodeoxyglucosepositronemissiontomographyfordifferentiatingmultiplesystematrophyparkinsonismtypefromparkinsonsdisease